Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933673 | 0.90 | ALDH1A1 (0.35) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL16065515 | 0.90 | OPRM1 (0.38) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL4740340 | 0.90 | ALDH1A1 (0.39) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL11470013 | 0.86 | ALDH1A1 (0.40) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL13755065 | 0.86 | SLC22A1 (0.39) | ALDH1A1POLBOPRM1SMN1; SMN2OPRD1 | |
| SCHEMBL15074623 | 0.83 | SMN1; SMN2 (0.38) | POLBOPRM1SMN1; SMN2OPRD1OPRK1 | |
| SCHEMBL12449741 | 0.83 | ALDH1A1 (0.37) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL12751319 | 0.82 | BRD4 (0.45) | ALDH1A1POLBLMNAHSD17B10OPRM1 | |
| SCHEMBL29220424 | 0.82 | SLC22A1 (0.39) | OPRM1SMN1; SMN2GAAOPRD1OPRK1 | |
| SCHEMBL24425843 | 0.82 | ALDH1A1 (0.49) | ALDH1A1OPRM1SMN1; SMN2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RES INSTITUTE CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4194092-B1 | SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2025-10-22 | — | — | EP | disclosed |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-09-23 | — | — | US | disclosed |
| US-12377407-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | CHONGQING PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| WO-2025097835-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | 重庆医药工业研究院有限责任公司 | 2025-05-15 | — | — | WO | disclosed |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2025-02-06 | — | — | US | disclosed |
| EP-4433451-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | Ecole Nationale Supérieure de Chimie de Rennes (FR) | 2024-09-25 | — | — | EP | disclosed |
| US-11794179-B2 | Synthesis and characterization of metathesis catalysts | UMICORE AG & CO. KG | 2023-10-24 | — | — | US | disclosed |
| US-11794179-B2 | Synthesis and characterization of metathesis catalysts | UMICORE AG & CO. KG | 2023-10-24 | — | — | US | disclosed |
| US-4956368-A | Antipsychotic agents | BRISTOL-MYERS COMPANY (US) | 1990-09-11 | — | — | US | disclosed |
| US-4906755-A | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0330824-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0330788-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0329905-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for increasing gastric motility | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329903-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329904-A1 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329902-A1 | Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0329932-A2 | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments | MERRELL PHARMACEUTICALS INC. (US) | 1989-08-30 | — | — | EP | disclosed |
| EP-0266730-A1 | Esters of hexadydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195481-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 2490/4885POLB 4833/4885LMNA 4079/4885 |
| US-12377407-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | PPOX, CYBA, CYBB | ALDH1A1 1395/4885POLB 316/4885LMNA 4173/4885 |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | SQLE, SYMPK, FDFT1 | ALDH1A1 1256/4885POLB 1763/4885LMNA 3721/4885 |
| US-11794179-B2 | Synthesis and characterization of metathesis catalysts | SQLE, FDFT1, FASN | ALDH1A1 1128/4885POLB 202/4885LMNA 3887/4885 |
| US-20250339411-A1 | GLP-1R AGONIST COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 2490/4885POLB 4833/4885LMNA 4079/4885 |
| US-12419874-B2 | GLP-1R agonist compound and use thereof | GLP1R, GIPR, GPR119 | ALDH1A1 2490/4885POLB 4833/4885LMNA 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.